Age-related macular degeneration remains a leading cause of vision impairment in adults over 50, affecting 196 million people globally. The burden is particularly acute for dry AMD patients: this form accounts for 90% of all AMD cases, yet only 10% of AMD patients have access to effective treatments. A groundbreaking development from Finnish researchers now offers potential relief for this underserved population. The new heat-based therapy uses controlled near-infrared light to activate cellular autophagy, enabling retinal cells to clear damaged proteins before vision-threatening accumulation occurs. This preventive approach marks a paradigm shift from reactive treatment strategies. Early laboratory evidence suggests the technique can stimulate cellular repair mechanisms safely and effectively. For the millions of dry AMD patients currently without therapeutic options, this innovation represents a meaningful step toward preserving vision and maintaining quality of life.
Read the full article on GMJ Newsroom.
Was this article helpful?
